1231 / 1416
Strategies of RTOG-1308:
a)The prescribed dose for this study is 70 Gy. The study is designed to
allow lower doses in situa;ons for which cri;cal structure constraints
cannot be met. A>er randomiza;on the pa;ent’s dose will be
individualized to the highest achievable dose (within normal ;ssue
organs-at-risk constraints) between 60-70 Gy;
b)Cross-over from protons to photons not permissable.
c)The protocol will maintain strict organs-at-risk constraints for this
trial;
d)The protocol will perform preliminary quality assurance review as
pa;ents are entered on the trial to monitor dose prescrip;ons and
dose/contouring compliance.